Molecular modeling of the three-dimensional structure of dopamine 3 (D 3) subtype receptor: Discovery of novel and potent D3 ligands through a hybrid pharmacophore- and structure-based database searching approach

Journal of Medicinal Chemistry

Volumn 46, Issue 21, 2003, Pages 4377-4392

  Varady, Judith ^a   Wu, Xihan ^a   Fang, Xueliang ^a   Min, Ji ^a   Hu, Zengjian ^a   Levant, Beth ^b   Wang, Shaomeng ^a  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF KANSAS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1,2,3,6 TETRAHYDRO 4 PHENYL 1 [(3 PHENYL 3 CYCLOHEXEN 1 YL)METHYL]PYRIDINE; 2 DIPROPYLAMINO 5 METHOXY 1 METHYLTETRALIN; 2 DIPROPYLAMINO 7 HYDROXYTETRALIN; 3 (1 PROPYL 3 PIPERIDINYL)BENZONITRILE; 3,4,4A,10B TETRAHYDRO 4 PROPYL 2H,5H [1]BENZOPYRANO[4,3 B][1,4]OXAZIN 9 OL; 5 METHOXY 1 METHYL 2 PROPYLAMINOTETRALIN; 7 DIPROPYLAMINO 2,3,5,6,7,8 HEXAHYDRONAPHTHO[2,3 B]FURAN; BP 897; CHLORPROMAZINE; CLOZAPINE; DOMPERIDONE; DOPAMINE 3 RECEPTOR; DOPAMINE RECEPTOR STIMULATING AGENT; ETICLOPRIDE; HALOPERIDOL; METOCLOPRAMIDE; NAFADOTRIDE; PRAMIPEXOLE; PRECLAMOL; QUINELORANE; QUINPIROLE; RACLOPRIDE; RHODOPSIN; ROPINIROLE; SPIPERONE; SULPIRIDE;

ARTICLE; DATA BASE; DRUG ACTIVITY; DRUG DEPENDENCE; DRUG SELECTIVITY; LIPID BILAYER; PARKINSON DISEASE; PHARMACOPHORE; RECEPTOR BINDING; SCHIZOPHRENIA; SCREENING; SEQUENCE HOMOLOGY; STRUCTURE ACTIVITY RELATION; STRUCTURE ANALYSIS; VALIDATION PROCESS; X RAY ANALYSIS;

ALGORITHMS; BINDING SITES; COMPUTATIONAL BIOLOGY; CRYSTALLOGRAPHY, X-RAY; DATABASES, PROTEIN; HUMANS; KINETICS; LIGANDS; LIPID BILAYERS; MODELS, MOLECULAR; MOLECULAR CONFORMATION; MUTATION; RECEPTORS, DOPAMINE D2; RECEPTORS, DOPAMINE D3; REPRODUCIBILITY OF RESULTS; SOLVENTS; STRUCTURE-ACTIVITY RELATIONSHIP; TETRAHYDRONAPHTHALENES; WATER;

EID: 0141992809     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm030085p     Document Type: Article

References (91)

1. 3 receptor as a therapeutic target for antipsychotic and antiparkinsonian drugs. Pharmacol. Ther. 2001, 90, 231-259.
2. Hackling, A. E.; Stark, H. Dopamine D3 receptor ligands with antagonist properties. ChemBioChem 2002, 3, 946-961.
3. Carroll, F. I.; Howell, L. L.; Kuhar, M. J. Pharmacotherapies for treatment of cocaine abuse: preclinical aspects. J. Med. Chem. 1999, 42, 2721-2731.
4. Montplaisir, J.; Nicolas, A.; Denesle, R.; Gomez-Mancilla, B. Restless legs syndrome improved by pramipexole: a double-blind randomized trial. Neurology 1999, 52, 938-943.
5. 2 agonist binding for determination of receptor subtype selectivity. J. Med. Chem. 1996, 39, 4233-4237.
6. 3 receptors. Mol. Pharmacol. 1994, 46, 299-312.
7. 3 receptor agonist. Nature 1999, 400, 371-375.
8. Wicke, K.; Garcia-Ladona, J. The dopamine D3 receptor partial agonist, BP 897, is an antagonist at human dopamine D3 receptors and at rat somatodendritic dopamine D3 receptors. Eur. J. Pharmacol. 2001, 424, 85-90.
9. 3 receptor antagonists and partial agonists. J. Med. Chem. 2002, 45, 4594-4597.
10. 1A receptor binding modes of the enantiomers of 5-OMe-BPAT. Bioorg. Med. Chem. 1999, 7, 1805-1820,
11. 2 receptor and its testing by docking of agonists and tricyclic antagonists. J. Med. Chem. 1994, 37, 2874-2888.
12. 3 receptors. Mol. Pharmacol. 1994, 46, 299-312.
13. Trumpp-Kallmeyer, S.; Hoflack, J.; Bruinvels, A.; Hibert, M. Modeling of G-protein-coupled receptors: application to dopamine, adrenaline, serotonin, acetylcholine, and mammalian opsin receptors. J. Med. Chem. 1992, 35, 3448-62.
14. 2-like dopamine receptors. Biochem. J. 1992, 287, 277-282.
15. 2 receptor. Proc. Natl. Acad. Sci. U.S.A. 1991, 88, 8111-8115.
16. Palczewski, K.; Kumasaka, T.; Hori, T.; Behnke, C. A.; Motoshima, H.; Fox, B. A.; Trong, I. L.; Teller, D. C.; Okada, T.; Stenkamp, R. E.; Yamamoto, M.; Miyano, M. Crystal structure of rhodopsin: a G protein-coupled receptor. Science 2000, 289, 739-745.
17. Teller, D. C.; Okada, T.; Behnke, C. A.; Palczewski, K.; Stenkamp, R. E. Advances in determination of a high-resolution three-dimensional structure of rhodopsin, a model of G-protein-coupled receptors (GPCRs). Biochemistry 2001, 40, 7761-7772.
18. Luecke, H.; Schobert, B.; Lanyi, J. K.; Spudich, E. N.; Spudich, J. L. Crystal structure of sensory rhodopsin II at 2.4 angstroms: insights into color tuning and transducer interaction. Science 2001, 293, 1499-1503.
19. Okada, T.; Fujiyoshi, Y.; Silow, M.; Navarro, J.; Landau, E. M.; Shichida, Y. Functional role of internal water molecules in rhodopsin revealed by X-ray crystallography. Proc. Natl. Acad. Sci. U.S.A. 2002, 99, 5982-5987.
20. Royant, A.; Nollert, P.; Edman, K.; Neutze, R.; Landau, E. M.; Pebay-Peyroula, E.; Navarro, J. X-ray structure of sensory rhodopsin II at 2. 1-A resolution. Proc. Natl. Acad. Sci. U.S.A. 2001, 98, 10131-10136.
21. Efremov, R. G.; Nolde, D. E.; Vergoten, G.; Arseniev, A. S. A solvent model for simulations of peptides in bilayers. II. Membrane-spanning α-helices. Biophys. J. 1999, 76, 2460-2471.
22. Botelho, A. V.; Gibson, N. J.; Thurmond, R. L.; Wang, Y.; Brown, M. F. Conformational energetics of rhodopsin modulated by nonlamellar-forming lipids. Biochemistry 2002, 41, 6354-6368.
23. Baldwin, J. M.; Schertler, G. F. X.; Unger, V. M. An Alpha-carbon template for the transmembrane helices in the rhodopsin family of G-protein-coupled receptors. J. Mol. Biol. 1997, 272, 144-164.
24. 2 receptor functionally coupled to adenylyl cyclase in Chinese hamster ovary cells. Mol. Pharmacol. 1995, 48, 344-351.
25. 3 receptors. FEBS Lett. 1999, 447, 251-256.
26. Heller, H.; Schaefer, M.; Schulten, K. Molecular dynamics simulation of a bilayer of 200 lipids in the gel and in the liquid-crystal phases. J. Phys. Chem. 1993, 97, 8343-8360.
27. Brooks, B. R.; Bruccoleri, R. E.; Olafson, B. D.; States, D. J.; Swaminathan, S.; Karplus, M. CHARMM: A Program for Macromolecular Energy, Minimization, and Dynamics Calculations. J. Comput. Chem. 1983, 4, 187-217.
28. Shi, L.; Javitch, J. A. The binding site of aminergic G protein-coupled receptors: the transmembrane segments and second extracellular loop. Annu. Rev. Pharmacol. Toxicol. 2002, 42, 437-467.
29. Ballesteros, J. A.; Shi, L.; Javitch, J. A. Stuctural mimicry in G protein-coupled receptors: implications of the high-resolution of rhodopsin for structure -function analysis of rhodopsin-like receptors. Mol. Pharmacol. 2001, 60, 1-19.
30. 2 dopamine receptor are important for binding and signal transduction. J. Neurochem. 1995, 65, 2105-15.
31. Sheikh, S. P.; Zvyaga, T. A.; Lichtarge, O.; Sakmar, T. P.; Bourne, H. R. Rhodopsin activation blocked by metal-ion-binding sites linking transmembrane helices C and F. Nature 1996, 383, 347-350.
32. Sheikh, S. P.; Vilardarga, J. P.; Baranski, T. J.; Lichtarge, O.; Iiri, T.; Meng, E. C.; Nissenson, R. A.; Bourne H. R. Similar structures and shared switch mechanisms of the β2-adrenoceptor and the parathyroid hormone receptor. Zn(II) bridges between helices III and VI block activation. J. Biol. Chem. 1999, 274, 17033-41.
33. Jensen, A. D.; Guarnieri, F.; Rasmussen, S. G. F.; Asmar, F.; Ballesteros, J. A.; Gether, U. Agonist-induced conformational changes at the cytoplasmic side of transmembrane segment 6 in the β2 adrenergic receptor mapped by site-selective fluorescent labeling. J. Biol. Chem. 2001, 276, 9279-9290.
34. Farrens, D. L.; Altenbach, C.; Yang, K.; Hubbell, W. L., Khorana, H. G. Requirement of rigid-body motion of transmembrane helices for light activation of rhodopsin. Science 1996, 274, 768-770.
35. Ballesteros, J. A.; Jensen, A. D.; Liapakis, G.; Rasmussen, S. G. F.; Shi, L.; Gether, U.; Javitch, J. A. Activation of the β2-adrenergic receptor involves disruption of an ionic lock between the cytoplasmic ends of transmembrane segments 3 and 6. J. Biol. Chem. 2001, 276, 29171-29177.
36. Gether, U.; Lin, S.; Ghanouni, P.; Ballesteros, J. A.; Weinstein, H.; Kobilka, B. K. Agonists induce conformational changes in thransmembrane domains III and Vi of the β2 adrenoceptor. EMBO J. 1997, 16, 6737-6747.
37. Javitch, J. A.; Fu, D.; Liapakis, G.; Chen, J. Constitutive activation of the β2 adrenergic receptor alters the orientation of its sixth membrane-spanning segment. J. Biol. Chem. 1997, 272, 18546-18549.
38. 2 receptor: Accessibility in the binding site crevice and position in the transmembrane bundle. Biochemistry 2001, 40, 12339-12348.
39. 2 receptor by the substituted-cysteine accessibility method. Neuron 1995, 14, 825-831.
40. 2 receptor exposed in the binding-site crevice. Biochemistry 1995, 34, 16433-39.
41. 2 ligands by their sensitivities to modification of the cysteine exposed in the binding-site crevice. Mol. Pharmacol. 1996, 49, 692-698.
42. 2 receptor is accessible in the binding-site crevice. Biochemistry 1998, 37, 998-1006.
43. 2 receptor: contributions of the second membrane-spanning segment. Biochemistry 1999, 38, 7961-68.
44. 2 receptor: accessibility in the binding-site crevice and position in the transmembrane bundle. Biochemistry 2000, 39, 12190-99.
45. 2 receptor accessible in the binding-site crevice. Biochemistry 1996, 35, 11278-85.
46. 3 receptors in Chinese hamster ovary cells. J. Pharmacol. Exp. Ther. 1999, 290, 908-916.
47. 3 receptor measured by guanosine 5′ -gamma-thio-triphosphate-35S-binding. J. Pharmacol. Exp. Ther. 1998, 285, 119-126.
48. 3 dopamine receptors. Neuropsychopharmacology 1995, 12, 335-345.
49. 2, a molecular modeling system, supplied by Accelrys Inc., San Diego, CA.
50. 3 dopamine receptors. J. Neurochem. 1999, 72, 2621-2624.
51. 3 receptor binding site by pharmacological characterization of mutants expressed in CHO cells with the Semliki Forest virus system J. Recept. Signal Transduct. Res. 1998, 18, 133-150.
52. Cotte, N.; Balestre, M. N.; Aumelas, A.; Mahe, E.; Phalipou, S.; Morin, D.; Hibert, M.; Manning, M.; Durroux, T.; Barberis, C.; Mouillac, B. Conserved aromatic residues in the transmembrane region VI of the V1a vasopressin receptor differentiate agonist vs antagonist ligand binding, Eur. J. Biochem. 2000, 267, 4253-63.
53. Chen, S.; Xu, M.; Lin, F.; Lee, D.; Riek, P.; Graham, R. M. Phe310 in transmembrane VI of the alpha1B-adrenergic receptor is a key switch residue involved in activation and catecholamine ring aromatic bonding. J. Biol. Chem. 1999, 274, 16320-30.
54. Noda, K.; Saad, Y.; Karnik, S. S. Interaction of Phe8 of angiotensin II with Lys199 and His256 of AT1 receptor in agonist activation. J. Biol. Chem. 1995, 270, 28511-14.
55. Spalding, T. A.; Burstein, E. S.; Henderson, S. C.; Ducote, K. R.; Brann, M. R. Identification of a ligand-dependent switch within a muscarinic receptor. J. Biol. Chem. 1998, 273, 21563-68.
56. Granas, C.; Nordvall, G.; Larhammar, D. Mutagenesis of the human 5-HT1B receptor: differences from the closely related 5-HT1A receptor and the role of residue F331 in signal transduction. J. Recept. Signal. Transduct. Res. 1998, 18, 225-241.
57. 3H] ketanserin binding to 5-hydroxytryptamine2 receptors. Mol. Pharmacol. 1993, 43, 755-761.
58. Kurogi, Y.; Guner, O. F. Pharmacophore modeling and three-dimensional database searching for drug design using catalyst. Curr. Med. Chem. 2001, 8, 1035-1055.
59. Milne, G. W.; Nicklaus, M. C.; Wang, S. Pharmacophores in drug design and discovery. SAR QSAR Environ. Res. 1998, 9, 23-38.
60. Wang, S.; Sakamuri, S.; Enyedy, I. J.; Kozikowski, A. P.; Deschaux, O.; Bandyopadhyay, B. C.; Tella, S. R.; Zaman, W. A.; Johnsons, K. M. Discovery of a novel dopamine transporter inhibitor, 4-hydroxy-1-methyl-4-(4-methylphenyl)-3-piperidyl 4-methylphenyl ketone, as a potential cocaine antagonist through 3D-database pharmacophore searching. Molecular modeling, structure-activity relationships, and behavioral pharmacological studies. J. Med. Chem. 2000, 43, 351-360.
61. Betti, L.; Botta, M.; Corelli, F.; Floridi, M.; Giannaccini, G.; Maccari, L.; Manetti, F.; Strappaghetti, G.; Tafi, A.; Corsano, S. Alpha(1) -adrenoceptor antagonists. 4. Pharmacophore-based design, synthesis and biological evaluation of new imidazo-, benzimidazo- and indoloarylpiperazine derivatives. J. Med. Chem. 2002, 45, 3603-3611.
62. Langer, T.; Hoffmann, R. D. Virtual screening: an effective tool for lead structure discovery? Curr. Pharm. Des. 2001, 7, 509-527.
63. Enyedy, I. J.; Ling, Y.; Nacro, K.; Tomita, Y.; Wu, X.; Cao, Y.; Guo, R. ; Li, B.; Zhu, X.; Huang, Y.; Long, Y. Q.; Roller, P. P.; Yang, D.; Wang, S. Discovery of small-molecule inhibitors of Bcl-2 through structure-based computer screening. J. Med. Chem. 2001, 44, 4313-4324.
64. Gradler, U.; Gerber, H.-D.; Goodenough-Lashua, D. M.; Garcia, G. A.; Ficner, R.; Reuter, K.; Stubbs, M. T.; Klebe, G. A new target for shigellosis: Rational design and crystallographic studies of inhibitors of tRNA-guanine transglycosylase. J. Mol. Biol. 2001, 306, 455-467.
65. Sarmiento, M.; Wu, L.; Keng, Y.-F.; Song, L.; Luo, Z.; Huang, Z.; Wu, G.-Z.; Yuan, A. K.; Zhang, Z.-Y. J. Med. Chem. 2000, 43, 146-155.
66. Perola, E.; Xu, K.; Kollmeyer, T. M.; Kaufmann, S. H.; Prendergast, F. G.; Pang, Y.-P. Successful Virtual screening of a chemical database for farnesyltransferase inhibitor leads. J. Med. Chem. 2000, 43, 401-408.
67. Iwata, Y.; Arisawa, M.; Hamada, R.; Kita, Y.; Mizutani, M. Y.; Tomioka, N.; Itai, A.; Miyamoto, S. Discovery of novel aldose reductase inhibitors using a protein structure-based approach: 3D-database search followed by design and synthesis. J. Med. Chem. 2001, 44, 1718-1728.
68. Debnath, A. K.; Radigan, L.; Jiang, S. Structure-based identification of small molecule antiviral compounds targeted to the gp41 core structure of the human immunodeficiency virus type 1. J. Med. Chem. 1999, 42, 3203-3209.
69. Quanta, a molecular modeling system, is supplied by Molecular Simulations Inc., San Diego, CA.
70. Milne, G. W. A.; Nicklaus, M. C.; Driscoll, J. S.; Wang, S.; Zaharevitz, D. W. The NCI Drug Information System 3D Database, J. Chem. Inf. Comput. Sci. 1994, 34, 1219-1224.
71. Chem-X is a product of Chemical Design Ltd., 7 West Way, Oxford OX2 0JB, England.
72. Sonesson, C.; Lin, C.-H.; Hansson, L.; Waters, N.; Svensson, K.; Carlsson, A.; Smith, M. W.; Wikstrom, H. Substituted (S)-Phenylpiperidines and rigid congeners as preferential dopamine autoreceptor antagonists: synthesis and structure-activity relationships. J. Med. Chem. 1994, 37, 2735-53.
73. Cheng, Y.; Prussoff, W. H. Relationship between the inhibition constant (Ki) and the concentration of inhibitor which causes 50% inhibition (IC50) of an enzymatic reaction. Biochem. Pharmacol. 1973, 22, 3099-3108.
74. Terp, G. E.; Johansen, B. N.; Christensen, I. T.; Jorgensen, F. S. A new concept for multidimensional selection of ligand conformations (MultiSelect) and multidimensional scoring (MultiScore) of protein-ligand binding affinities. J. Med. Chem. 2001, 44, 2333-2343.
75. MacKerell, A. D., Jr.; Bashford, D.; Bellott, M.; Dunbrack, R. L., Jr.; Evanseck, J. D.; Field, M. J.; Fischer, S.; Gao, J.; Guo, H.; Ha, S.; Joseph-McCarthy, D.; Kuchnir, L.; Kuczera, K.; Lau, F. T. K.; Mattos, C.; Michnick, S.; Ngo, T.; Nguyen, D. T.; Prodhom, B.; Reiher, W. E., III; Roux, B. ; Schlenkrich, M.; Smith, J. C.; Stote, R.; Straub, J.; Watanabe, M.; Wiorkiewicz-Kuczera, J.; Yin, D.; Karplus, M. All-atom empirical potential for molecular modeling and dynamics studies of proteins. J. Phys. Chem. B 1998, 102, 3586-3616.
76. Feller, S. E.; Gawrisch, K.; MackKerell, A. D., Jr. Polyunsaturated fatty acids in lipid bilayers: intrinsic and environmental contributions to their unique physical properties. J. Am. Chem. Soc. 2002, 124, 318-326.
77. Carpenter, G. A.; Grossberg, S. ART 2: Self-organization of stable category recognition codes for analog input patterns. Appl. Opt. 1987, 26, 4919-4930.
78. Karpen, M. E.; Tobias, D. T.; Brooks, C. L., III Statistical clustering techniques for analysis of long molecular dynamics trajectories. I: Analysis of 2.2 ns trajectories of YPGDV. Biochemistry 1993, 32, 412-420.
79. Godden, J. W.; Xue, L.; Bajorath, J. Combinatorial Preferences Affect Molecular Similarity/Diversity Calculations Using Binary Fingerprints and Tanimoto Coefficients. J. Chem. Inf. Comput. Sci. 2000, 40, 163-166.
80. 3 dopamine receptor. J. Pharmacol. Exp. Ther. 1994, 268, 417-426.
81. 3 dopamine receptors. Bioorg. Med. Chem. 2000, 8, 321-327.
82. 2 agonist pharmacophore. Structure-activity relationships of a series of 2-(aminomethyl)chromans. J. Med. Chem. 1997, 40, 4235-4256.
83. 3 receptor antagonists (+)-S14297, nafadotride, GR103, 691 and U99194. J. Pharmacol. Exp. Ther. 1998, 287, 187-197.
84. 3 dopamine receptor to ligand binding and sensitivity to external oxidizing agents. Br. J. Pharmacol. 1998, 125, 705-710.
85. 2 receptors elicits prolactin secretion and catalepsy. J. Pharmacol. Exp. Ther. 1995, 275, 885-898.
86. 3 receptors. Neuropharmacology 1995, 34, 1693-1696.
87. Nader, M. A.; Green, K. L.; Luedtke, R. R.; Mach, R. H. The effects of benzamide analogues on cocaine self-administration in rhesus monkeys. Psychopharmacology 1999, 147, 143-152.
88. 3 receptors: I. Receptorial, electrophysiological and neurochemical profile compared with GR218,231 and L741,626. J. Pharmacol. Exp. Ther. 2000, 293, 1048-1062.
89. Pugsley, T. A.; Davis, M. D.; Akunne, H. C.; Cooke, L. W.; Whetzel, S. Z.; MacKenzie, R. G.; Shih, Y. H.; van Leeuwen, D. H.; DeMattos, S. B.; Georgic, L. M. CI-1007, a dopamine partial agonist and potential antipsychotic agent. I. Neurochemical effects. J. Pharmacol. Exp. Ther. 1995, 274, 898-911.
90. Sonesson, C.; Waters, N.; Svensson, K.; Carlsson, A.; Smith, M. W.; Piercey, M. F.; Meier, E.; Wikstrom, H. Substituted 3-phenylpiperidines: new centrally acting dopamine autoreceptor antagonists. J. Med. Chem. 1993, 36, 3188-3196.
91. Stjernlof, P.; Lin, C.-H.; Sonesson, C.; Svensson, K.; Smith, M. W. (Dipropylamino)-tetrahydronaphthofurans: centrally acting serotonin agonists and dopamine agonists-antagonists. Bioorg. Med. Chem. Lett. 1997, 7, 2759-2764.